Stay updated with breaking news from எட்மண்ட் கிம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Gilead's Kite bets on early-stage biotech to advance allogeneic cell therapies biopharmadive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharmadive.com Daily Mail and Mail on Sunday newspapers.
Published: May 11, 2021 By Heather McKenzie Appia co-founder and chief executive officer, JJ Kang/Photo Courtesy of Appia Bio Backed by $52 million in Series A financing led by 8VC and named after a feat of engineering in ancient Rome, Appia Bio jumped into the cell therapy fray this morning with a promising scalable technology platform. “The company is named after the Aqua Appia, which is the first Roman aqueduct. It was kind of a feat of engineering and it brought water to a lot more people, and that thematically connects well. We want to engineer these cells and provide a broader reach for cell therapy through allogeneic off-the-shelf,” said Appia co-founder and chief executive officer, JJ Kang, Ph.D. ....
Appia Bio Launches With $52 Million Series A Financing and Establishes Scientific Advisory Board Proceeds will be used to progress stem cell derived CAR-engineered invariant natural killer T cells (CAR-iNKT) to the clinic in hematological and solid tumor indications News provided by Share this article Share this article LOS ANGELES, May 11, 2021 /PRNewswire/ Appia Bio, Inc., an early stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, today announced its launch from stealth backed by $52 million Series A financing led by 8VC. Other investors included Two Sigma Ventures, among others, and participation from seed investors Sherpa Healthcare Partners and Freeflow Ventures. ....